• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Tirofiban in the treatment of cancer-associated ischemic stroke
CONCLUSIONS: Early administration of tirofiban in the treatment of mild to moderate ischemic stroke is safe, which can reduce 24-hour and 7-day NIHSS scores and has potential value.PMID:37140310 | DOI:10.26355/eurrev_202304_32142
Source: Pharmacological Reviews - May 4, 2023 Category: Drugs & Pharmacology Authors: Z-M Zhang Z-H Lin G-L Zhu Source Type: research

Platelet Count Predicts Adverse Clinical Outcomes After Ischemic Stroke or TIA: Subgroup Analysis of CNSR II
Conclusion: In ischemic stroke or TIA patients with platelet count within normal range, platelet count may be a qualified predictor for long-term recurrent stroke, mortality, and poor functional outcome. Introduction Platelets exert a critical role in the pathogenesis of atherosclerotic complications of cardio-cerebrovascular disease, contributing to thrombus formation, and embolism (1, 2). Previous literature reported that platelets of various size and density are produced by megakaryocytes of different size and stages of maturation in different clinical conditions, suggesting various platelet patterns in differen...
Source: Frontiers in Neurology - April 11, 2019 Category: Neurology Source Type: research

Is a Routine Head CT after IV-tPA Therapy Medically Necessary? (P03.170)
CONCLUSIONS: In clinical practice, the risk of symptomatic ICH after IV-tPA is low. GRASPS scores may be helpful in identifying patients at higher risk for ICH but it is not sufficiently sensitive to guide a selective use for post-therapy surveillance imaging. A protocol requiring repeat neuroimaging at 24 hr after IV-tPA is not supported by clinical practice data. Neuroimaging after IV-tPA should focus on vascular imaging needed for determining the mechanism and treatment plan and to evaluate the cause of clinical deterioration after therapy.Disclosure: Dr. Sehgal has nothing to disclose. Dr. Mehndiratta has nothing to di...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Sehgal, S., Mehndiratta, P., Talahma, M., Eisele, S., Sila, C. Tags: P03 Cerebrovascular Disease III Source Type: research